11
Downloads
8
Episodes
Our Vision is to bridge the gap between medical innovations and the global medical community, becoming the authoritative voice in journalistic coverage of medical conferences. By covering a wide spectrum of therapeutic areas and partnering with top-tier journalists and camera crews, we create content that not only informs but also inspires and drives action within the medical sector.
Episodes
Monday Apr 01, 2024
Monday Apr 01, 2024
In today's podcast, we talk with Dr. Brian Weinshenker of the Mayo Clinic about innovative ways to do clinical trials involving neuromyelitis optica spectrum disorder, or NMOSD. We spoke with him at the ECTRIMS congress.
More than a dozen years ago, NMOSD was redefined as a separate disease from multiple sclerosis, thanks to the discovery of the first biomarker for it, an antibody against aquaporin-4, leading to consensus diagnostic criteria for NMOSD. With these criteria in mind, Dr. Weinshenker discusses strategies for better clinical trials in NMOSD.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.